Exploring High Growth Tech Stocks In February 2025

In a global market marked by volatility, with U.S. stocks mostly lower due to AI competition fears and mixed economic signals from major economies, investors are closely watching the technology sector for potential high-growth opportunities. As earnings season unfolds and central banks adjust their monetary policies, identifying tech stocks that can navigate competitive pressures and capitalize on innovation becomes crucial for those seeking growth in this dynamic environment.

Top 10 High Growth Tech Companies

Name	Revenue Growth	Earnings Growth	Growth Rating
Shanghai Baosight SoftwareLtd	21.82%	25.22%	★★★★★★
Seojin SystemLtd	35.41%	39.86%	★★★★★★
Clinuvel Pharmaceuticals	21.39%	26.17%	★★★★★★
eWeLLLtd	26.41%	28.82%	★★★★★★
Yggdrazil Group	30.20%	87.10%	★★★★★★
Medley	20.95%	27.32%	★★★★★★
Mental Health TechnologiesLtd	25.83%	113.12%	★★★★★★
JNTC	29.48%	104.37%	★★★★★★
Dmall	29.53%	88.37%	★★★★★★
Delton Technology (Guangzhou)	20.25%	29.52%	★★★★★★

Click here to see the full list of 1229 stocks from our High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Genmab (CPSE:GMAB)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Genmab A/S is a biotechnology company focused on developing antibody therapeutics for cancer and other diseases, with a market capitalization of DKK88.52 billion.

Operations: The company generates revenue of DKK19.84 billion from its biotechnology segment, focusing on antibody therapeutics for cancer and other diseases.

Genmab's recent performance in the biotech sector underscores its innovative edge, particularly with its flagship product, DARZALEX, which achieved robust sales of USD 11.67 billion in 2024. This achievement is complemented by promising clinical trial outcomes for epcoritamab, demonstrating a 100% overall response rate in certain high-risk patient cohorts. With R&D expenses aligning closely with these breakthroughs, Genmab not only surpasses industry growth rates but also showcases a potential trajectory for sustained leadership in oncology treatments. These developments are pivotal as they reflect both the company's commitment to advancing healthcare and its capability to deliver on high-stakes projects—a testament to its growing influence in biotech innovations.

• Click here and access our complete health analysis report to understand the dynamics of Genmab.

• Explore historical data to track Genmab's performance over time in our Past section.

Yubico (OM:YUBICO)

Simply Wall St Growth Rating: ★★★★★★

Overview: Yubico AB offers authentication solutions for computers, networks, and online services with a market cap of SEK22.48 billion.

Operations: With a focus on authentication solutions, Yubico AB generates revenue primarily from its Security Software & Services segment, amounting to SEK2.28 billion.

Yubico's recent strategic moves and robust financial performance underscore its potential in the tech landscape. The company's earnings surged by 109.7% over the past year, outpacing the software industry's growth of 40.1%. This momentum is expected to continue with an annual earnings growth forecast at 29.9%, significantly above Sweden's market average of 13.4%. In a pivotal collaboration, Yubico deployed over 200,000 FIDO2 YubiKeys with T-Mobile US to enhance security protocols, demonstrating its commitment to pioneering advanced authentication solutions in response to escalating cyber threats. This initiative not only solidifies Yubico’s role in shaping future security standards but also positions it advantageously within the burgeoning field of passwordless technology.

• Delve into the full analysis health report here for a deeper understanding of Yubico.

• Review our historical performance report to gain insights into Yubico's's past performance.

Kakaku.com (TSE:2371)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kakaku.com, Inc., along with its subsidiaries, offers purchase support and restaurant review services in Japan, with a market capitalization of ¥479.99 billion.

Operations: Kakaku.com, Inc. provides a range of services in Japan, focusing on purchase support and restaurant reviews. The company operates through various revenue segments without including any segment adjustments or unallocated amounts in their financial data.

Kakaku.com has demonstrated a robust growth trajectory, with earnings expanding by 10.0% annually, outstripping the Japanese market average of 8.0%. This performance is underpinned by a significant commitment to innovation, as evidenced by its R&D expenditure which has consistently aligned with industry demands—last year alone, R&D spending accounted for a substantial portion of revenue. The firm's strategic decision to divest from its subsidiary Pathee Inc., as discussed in their recent board meeting, reflects a focused approach to streamline operations and invest in core areas that promise higher returns. This strategy, coupled with an anticipated revenue increase of 9.2% per year—more than double the national forecast of 4.2%—positions Kakaku.com advantageously within the competitive tech landscape in Japan.

• Dive into the specifics of Kakaku.com here with our thorough health report.

• Learn about Kakaku.com's historical performance.

Make It Happen

• Unlock our comprehensive list of 1229 High Growth Tech and AI Stocks by clicking here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com